Vancouver, Wash.-based Absci is exploring a consumer-focused approach to drug development as it advances ABS-201, an AI-designed antibody being developed for male pattern hair loss and endometriosis. CEO Sean McClain envisions developing upgraded versions of the drug over time, potentially adding new capabilities.
Inside Absci’s Quest to Become the Apple of Biotech
Share: